Leonteq Securities AG purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund purchased 18,922 shares of the medical equipment provider’s stock, valued at approximately $1,804,000.
Other hedge funds also recently added to or reduced their stakes in the company. ABN Amro Investment Solutions grew its stake in Boston Scientific by 22.5% in the 4th quarter. ABN Amro Investment Solutions now owns 687,007 shares of the medical equipment provider’s stock worth $65,506,000 after acquiring an additional 126,088 shares in the last quarter. Rathbones Group PLC grew its stake in Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after acquiring an additional 477,680 shares in the last quarter. Little House Capital LLC grew its stake in Boston Scientific by 34.7% in the 4th quarter. Little House Capital LLC now owns 13,373 shares of the medical equipment provider’s stock worth $1,275,000 after acquiring an additional 3,443 shares in the last quarter. Atle Fund Management AB grew its stake in Boston Scientific by 25.4% in the 4th quarter. Atle Fund Management AB now owns 108,682 shares of the medical equipment provider’s stock worth $10,363,000 after acquiring an additional 22,002 shares in the last quarter. Finally, Fairtree Asset Management Pty Ltd bought a new position in Boston Scientific in the 4th quarter worth about $1,171,000. 89.07% of the stock is currently owned by institutional investors.
Insider Transactions at Boston Scientific
In other Boston Scientific news, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.
Boston Scientific News Roundup
- Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Insider purchases are often viewed as a sign of management confidence in the company’s outlook and can support sentiment around the stock.
- Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. The FRACTURE trial met all primary safety and effectiveness endpoints, which strengthens the case for a future regulatory submission and supports the company’s growth story in interventional cardiology.
- Neutral Sentiment: Baird kept an Outperform rating on Boston Scientific, though it trimmed its price target to $75 from $78. That suggests the firm still sees upside, but the lower target may temper enthusiasm somewhat.
- Negative Sentiment: Recent commentary also pointed to Boston Scientific having fallen on weak results, and the stock remains well below its longer-term moving averages. That indicates investors are still weighing execution concerns and broader pressure on the shares despite the upbeat insider and clinical developments.
Boston Scientific Price Performance
Shares of BSX opened at $57.08 on Friday. The company has a 50 day moving average price of $62.21 and a 200-day moving average price of $80.40. Boston Scientific Corporation has a fifty-two week low of $52.52 and a fifty-two week high of $109.50. The stock has a market capitalization of $84.84 billion, a PE ratio of 23.88, a PEG ratio of 1.04 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the prior year, the company earned $0.75 EPS. The company’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.
Boston Scientific announced that its board has approved a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.
Analyst Ratings Changes
A number of brokerages have commented on BSX. TD Cowen dropped their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research note on Monday, February 2nd. Jefferies Financial Group dropped their target price on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Canaccord Genuity Group dropped their target price on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd. Finally, Citigroup dropped their target price on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $92.71.
View Our Latest Stock Analysis on BSX
Boston Scientific Company Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
- Five stocks we like better than Boston Scientific
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
